search case studies

 

  News and Events    
 
 


SHI supports global consortium reporting HIV vaccine breakthrough

24 September 2009 - A Phase III clinical trial involving more than 16,000 adult volunteers in Thailand has demonstrated that an investigational HIV vaccine regimen was safe and, for the first time, modestly effective in preventing HIV infection. According to final results released by the trial sponsor, the U.S. Army Surgeon General, the prime boost combination of ALVAC® HIV and AIDSVAX® B/E lowered the rate of HIV infection by 31.2% compared with placebo. Please click here for the sponsor’s press release.
 
This finding has important implications for the design of future HIV vaccines and how they are tested, though additional research is needed to better understand how this vaccine regimen reduced the risk of HIV infection. Given the significant threat of HIV infection worldwide, an efficacious vaccine is urgently needed, as part of a broader prevention effort to help control the epidemic.
 
Over the past few years, SHI Consulting has been privileged to support strategic, scientific and communication planning for the global consortium undertaking this important study, referred to as RV144. Collaborating partners include the U.S. Army, the Thai Ministry of Public Health, the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, sanofi pasteur, and Global Solutions for Infectious Diseases (GSID).
 
SHI congratulates all partners, and especially the more than 16,000 Thai volunteers who participated in the study, on this achievement. We look forward to continuing to work with the consortium as it develops and implements plans to build on this scientifically important result.

Date: 2009-09-24
Source:

 

 
"SHI Consulting has consistently provided strategic and creative insight and delivered its services with great skill and dedication"
Joseph Rotman